Form 8-K - Current report:
SEC Accession No. 0001815776-25-000017
Filing Date
2025-03-19
Accepted
2025-03-19 16:08:30
Documents
15
Period of Report
2025-03-19
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20250319.htm   iXBRL 8-K 27786
2 EX-99.1 a991q424pressrelease.htm EX-99.1 65921
6 lenzlogoa.jpg GRAPHIC 2890
  Complete submission text file 0001815776-25-000017.txt   236523

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20250319.xsd EX-101.SCH 1770
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20250319_lab.xml EX-101.LAB 23433
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20250319_pre.xml EX-101.PRE 13570
18 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20250319_htm.xml XML 3041
Mailing Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075
Business Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 25752752
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)